SOX18 expression predicts response to platinum-based chemotherapy in ovarian cancer

Bartosz Pula; Christopher Kobierzycki; Daniel Solinski; Matuesz Olbromski; Ewa Nowak-Markwitz; Marek Spaczynski; Witold Kedzia; Maciej Zabel; Piotr Dziegiel

SOX18 expression predicts response to platinum-based chemotherapy in ovarian cancer

Anticancer Res. 2014 Aug;34(8):4029-37.

Authors

Bartosz Pula¹, Christopher Kobierzycki², Daniel Solinski², Matuesz Olbromski², Ewa Nowak-Markwitz³, Marek Spaczynski³, Witold Kedzia⁴, Maciej Zabel⁵, Piotr Dziegiel⁶

Affiliations

¹ Department of Histology and Embryology, Medical University in Wroclaw, Wroclaw, Poland bartosz.pula@umed.wroc.pl.
² Department of Histology and Embryology, Medical University in Wroclaw, Wroclaw, Poland.
³ Department of Gynecologic Oncology, University of Medical Sciences in Poznan, Poznan, Poland.
⁴ Department of Gynecology, University of Medical Sciences in Poznan, Poznan, Poland.
⁵ Department of Histology and Embryology, Medical University in Wroclaw, Wroclaw, Poland Department of Histology and Embryology, University of Medical Sciences in Poznan, Poznan, Poland.
⁶ Department of Histology and Embryology, Medical University in Wroclaw, Wroclaw, Poland Department of Physiotherapy, University School of Physical Education in Wroclaw, Wroclaw, Poland.

PMID: 25075026

Abstract

Background: SOX18 is a transcription factor known to be involved in blood and lymphatic vessel, hair follicle development, and wound healing processes. In addition, it has been reported that SOX18 may influence cancer growth. The role of SOX18 expression in ovarian cancer (OC) has not been determined.

Materials and methods: SOX18 expression was assessed in 85 OC cases using immunohistochemical methods and in ovarian cancer cell lines on the mRNA and protein level.

Results: SOX18 was expressed in cancer cell nuclei as well as the cytoplasm. Higher nuclear SOX18 expression was associated with presence of residual disease following surgical treatment (p=0.0158) and advanced disease stage (p=0.0056). Univariate survival analysis revealed that high SOX18 (p=0.0125) expression, presence of residual disease (p<0.0001) and advanced disease stage (p<0.0324) predicted poor patient outcome.

Conclusion: SOX18 may be a new predictive marker for OC.

Keywords: Ovarian cancer; SOX18; chemotherapy; prognosis.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Cell Line, Tumor
Female
Humans
Immunohistochemistry
Ovarian Neoplasms / drug therapy*
Ovarian Neoplasms / mortality
Ovarian Neoplasms / pathology
Platinum / therapeutic use
SOXF Transcription Factors / analysis
SOXF Transcription Factors / genetics
SOXF Transcription Factors / physiology*

Substances

SOX18 protein, human
SOXF Transcription Factors
Platinum